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Clinical Relevancy Statement
Trace elements (TEs) including zinc, selenium, copper, 
manganese, and chromium are essential components of 
parenteral nutrition (PN). Guidelines are available for 
the daily trace element maintenance requirements and 
supplementation in PN, but these have not addressed 
the long term TE requirements for home PN patients. 
Study results show that a fixed dose of the parenteral 
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multi-trace element product continues to be commonly 
used for home PN patients. This practice may contribute 
to excessive copper, manganese, and chromium loading 
and may provide less than optimal zinc and selenium 
intake. Furthermore, monitoring of TE status in home 
PN patients is infrequent and inconsistent. Therefore, 
parenteral TE supplementation in home PN should be 
individualized based on regular monitoring of TE status 
and considering the patient’s underlying clinical 
conditions.
Introduction
Home parenteral nutrition (PN) is a life-saving therapy 
for patients with intestinal failure. Trace elements (TEs), 
including zinc, selenium, copper, manganese, and chro-
mium, are micronutrients that serve different physiologic 
functions and are routinely supplemented in PN. Although 
TEs are required in relatively small amounts, their exact 
requirements vary with the individual’s nutrition status 
and clinical conditions. Guidelines for adult parenteral 
zinc, copper, manganese, and chromium requirements 
were first released in 1979 by the American Medical 
Background: Trace elements (TEs) dosing and monitoring in 
home parenteral nutrition (PN) patients vary with their underly-
ing conditions. Methods: This retrospective observational study 
evaluated parenteral TE dosing, serum TE concentrations and 
monitoring, and dose-concentration relationships between TE 
doses and serum TE concentrations in 26 adult and adolescent 
home PN patients. Results: There was a total of 40,493 PN days. 
Average parenteral zinc doses of 9.1 mg/d and 7.6 mg/d resulted 
in the majority of serum zinc concentrations (90%) within nor-
mal range in patients with and without short bowel syndrome 
(SBS), respectively. Selenium at about 70 mcg/d resulted in 
about 60% of serum selenium concentrations within normal 
range, with 38% of values below normal in patients with and 
without SBS alike. Copper at 1 mg/d resulted in 22.5% of serum 
copper concentrations above the normal range. The majority of 
serum manganese (94.6%) and chromium (96%) concentrations 
were elevated. Serum TE concentrations were infrequently 
monitored. Significant relationships existed between doses and 
serum concentrations for zinc (P < .0001), manganese (P = 
.012), and chromium (P < .0001) but not for selenium or cop-
per. Conclusions: TE doses in home PN should be individualized 
and adjusted based on regular monitoring of TE status. In long-
term home PN patients, higher zinc and selenium doses may be 
necessary to maintain their normal serum concentrations. 
Lower copper doses and restrictions of manganese and chro-
mium supplementation may be needed to avoid their accumula-
tion. Relationships between TE doses and serum TE 
concentrations vary for each TE and underlying clinical condi-
tions. (JPEN J Parenter Enteral Nutr. 2011;35:736-747)
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Association (AMA)1 and updated by the New York 
Academy of Medicine and the AMA in 1984 (Table 1).2 
The AMA guidelines have been used as a reference by the 
US Food and Drug Administration (FDA) for the labeling 
of parenteral multi-TE products, which have become the 
standard for TE dosing in PN. Following reports of TE 
imbalances in PN patients who received parenteral TE 
supplements based on the AMA guidelines,2-4 the 
American Society for Parenteral and Enteral Nutrition 
(A.S.P.E.N.) released different guidelines for daily TE 
maintenance requirements and supplementation in PN in 
1998 that were later revised in 2004 with added selenium 
recommendations (Table 1).5,6
TE supplementation and dose adjustments in PN are 
generally guided by serum TE concentrations. However, 
clinical conditions that alter TE clearance diversely affect 
serum TE concentrations. For instance, malabsorption 
syndromes such as short bowel syndrome (SBS), high 
fluid output enterocutaneous fistulas, and chronic 
diarrhea result in substantial zinc and selenium losses, 
which necessitate supplementation with higher than the 
recommended maintenance doses that are found in the 
multi-TE products. Conversely, patients with decreased 
bile flow such as hepatic cholestasis may require lower 
copper and manganese supplementation to avoid their 
accumulation, as both TEs are mainly eliminated via the 
bile and may accumulate to toxic levels, especially man-
ganese.7-9 Furthermore, manganese and chromium are 
known contaminants of the parenteral products used in 
the making of PN and provide additional intake that 
exceeds the maintenance requirements.10-12 Although TE 
supplements are relatively safe, identifying the exact TE 
requirements in PN is challenged by the poor correlation 
of serum TE concentrations with tissue TE stores and the 
presence of underlying clinical conditions that variably 
affect TE balance. The fixed-dose parenteral multi-TE 
formulation that is based on the old AMA guidelines con-
tinues to be used in PN despite its provision of excessive 
copper, manganese, and chromium. Furthermore, the 
effects of TE dosing based on the A.S.P.E.N. TE dosing 
guidelines on serum TE concentrations have not been 
tested in long-term home PN patients.
The primary objectives of this study were to evaluate 
parenteral TE dosing, serum TE concentrations, and the 
frequency of serum TE monitoring in patients who 
received long-term home PN. The secondary objectives 
were to explore the relationships between parenteral TE 
doses and their respective serum TE concentrations, 
compare the doses and serum concentrations of zinc and 
selenium in patients with and without SBS, and compare 
the doses and serum concentrations of copper and man-
ganese in patients with and without cholestasis.
Methods
This was a retrospective observational study that evaluated 
parenteral TE dosing, serum TE concentrations, and the 
frequency of monitoring serum TE concentrations in adult 
and adolescent home PN patients. Parenteral TE doses in 
PN were compared to the A.S.P.E.N. TE dosing guidelines. 
Serum TE concentrations were compared to reference 
ranges. Furthermore, the study explored the relationships 
between TE doses and their serum concentrations. The 
study was approved by the institutional review board.
Patients
Adult and adolescent patients >40 kg and who received 
home PN for at least 1 year (365 days) between May 1, 
2002, and April 30, 2007, through a home infusion pro-
vider affiliated with a large university health system were 
identified using the home infusion pharmacy electronic 
database. The body weight >40 kg was used to classify 
patients as adolescents or adults, in accordance with the 
A.S.P.E.N. parenteral TE dosing guidelines (Table 1). 
Table 1.  Parenteral Trace Element Daily Supplementation Guidelines and Commercial Multitrace-5 Concentrate 
Injectiona
Zinc, mg Selenium, mcg Copper, mg Manganese, mg Chromium, mcg
AMA (1979)1 2.5−4 — 0.5−1.5 0.15−0.8 10−15
New York Academy of Medicine 
 and AMA (1984)2 2.5−4 50−60 0.3−0.5 0.4−0.8 10−20
A.S.P.E.N. (1998)5
 Adults 2.5−5 — 0.3−0.5 0.06−0.1 10−15
A.S.P.E.N. (2004)6
 Adults >40 kg 2.5−5 20−60 0.3−0.5 0.06−0.1 10−15
 Adolescents >40 kg 2−5 40−60 0.2−0.5 0.04−0.1 5−15
Multitrace-5 Concentrate  
  Injectiona (1 mL) 5 60 1 0.5 10
AMA, American Medical Association; A.S.P.E.N., American Society of Parenteral and Enteral Nutrition.
aAmerican Regent, Inc (Shirley, NY).
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Data were extracted from patients’ medical records of the 
home infusion provider and the university health system. 
The medical records of identified patients were reviewed 
retrospectively beginning with their first day of PN avail-
able on the pharmacy records starting from June 20, 1995, 
and ending August 31, 2008. Collected data included 
patients’ age, gender, and body weight; indication(s) for 
home PN; PN start and stop dates; PN administration 
dates and frequency; doses of zinc, selenium, copper, 
manganese, and chromium in each PN prescription; 
serum TE concentrations; serum creatinine; and direct 
bilirubin concentrations, which were used to define cho-
lestasis as the time period between serum direct bilirubin 
concentrations ≥2 mg/dL until the next measured serum 
direct bilirubin concentration was <2 mg/dL.
Data Extraction and Collection
Data were extracted using a modified version of 
RapidMiner (YALE open-source software; Rapid-I GmbH, 
Dortmund, Germany). A subject-based relational data-
mining procedure was used to search multiple electronic 
patient tables and charts. Data were manually entered 
into an Excel (Microsoft, Redmond, WA) spreadsheet in 
a highly abstracted form (eg, TE dose per PN administra-
tion day, frequency, start and stop dates) and then con-
verted to average daily and weekly TE dose for the entire 
duration of PN therapy. Data were entered using a paired 
key variable-matching method (unique patient study ID 
and date). In instances of duplicate or multiple records of 
a key, the information was combined and replaced by the 
aggregate mean. Validation procedures, consisting of 
double checks of entries, ensured the accuracy of manu-
ally entered data.
Collection and Assays of TE Blood Samples
Appropriate techniques for collection and preparation of 
blood TE samples were followed to minimize exogenous 
trace metal contamination. Metal-free syringes and stain-
less steel phlebotomy needles were used for venipunc-
ture. Blood samples were collected in specifically 
designed metal-free royal blue–top tubes with no addi-
tives. After centrifugation, serum aliquots were trans-
ferred into metal-free containers or plastic vials while 
avoiding transfer of the cellular components of blood. 
Serum TE concentrations were analyzed and reported 
from 2 different laboratories (Mayo Medical Laboratories 
and The University of Michigan Health System 
Laboratories). Serum zinc and copper samples were 
assayed using graphite furnace atomic absorption. Serum 
selenium, manganese, and chromium samples were 
assayed using inductively coupled plasma–mass spec-
trometry (ICP-MS).
Data Analysis
The appropriateness of parenteral TE dosing was evalu-
ated based on comparisons with the 2004 A.S.P.E.N. 
parenteral TE supplementation guidelines (Table 1). TE 
doses were categorized as below, within, or above the 
A.S.P.E.N.’s supplementation range for each TE. Similarly, 
serum TE concentrations were classified as below, within, 
or above in comparison to the reference serum concentra-
tion ranges. Group comparisons were performed for zinc 
and selenium doses and serum TE concentrations, based 
on the presence or absence of SBS. Group comparisons 
were also performed for copper and manganese doses 
based on the presence or absence of cholestasis. Because 
chromium and manganese were omitted at times from 
PN, serum chromium and manganese concentrations 
were compared during the times when patients did or did 
not receive either TE. The frequency of measuring each 
serum TE per year (365 days) was calculated. Because 
PN was administered daily or intermittently, average 
weekly TE doses were used to assess the relationships 
between TE doses and serum TE concentrations.
Statistical Analysis
Parenteral TE doses and underlying clinical conditions 
(SBS and cholestasis) were the independent variables, 
and serum TE concentrations were the dependent vari-
ables. A linear mixed model was used for comparative 
analyses. A linear regression mixed model was used to 
predict the relationship between TE doses and serum TE 
concentrations. Negative binomial regression analysis 
was used to predict the frequency of measured serum TE 
concentrations. Statistical analyses were performed using 
SAS software (version 9.2; SAS Institute, Inc, Cary, NC).
Table 2.  Descriptive Characteristics of Home 
Parenteral Nutrition (PN) Patients
No. (%)
Gender
 Male 7 (27)
 Female 19 (73)
Age, y, range 14−71.5
Weight, kg, range 40.2−132
Indications for home PN
 Short bowel syndrome 10 (38)
 Enterocutaneous fistula(s) 4 (15)
 Chronic pancreatitis 3 (11.5)
 Crohn’s disease 3 (11.5)
 Gastroparesis 2 (8)
 Small bowel amyloidosis 2 (8)
 Familial pseudo-obstruction 1 (4)
 Gastrointestinal dysmotility 1 (4)
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Results
Patient Characteristics (Table 2)
There was a total of 26 patients (24 adults and 2 adoles-
cents), with 7 males (27%) and 19 females (73%). During 
the study period, patients’ age ranged from 14–71.5 years, 
and their body weight ranged from 40.2–132 kg. The 
most common indications for home PN were SBS (n = 
10; 38%), enterocutaneous fistula(s) (n = 4; 15%), chronic 
pancreatitis (n = 3; 11.5%), and Crohn’s disease (n = 3; 
11.5%). Five patients developed cholestasis intermittently 
during their course of PN therapy. No clinical signs or 
symptoms of TE deficiencies or toxicities were observed.
PN
The total cumulative number of home PN days was 
40,493, including 28,957 days (71.5%) of PN as the only 
source of nutrition and 11,536 days (28.5%) of supple-
mental PN for patients who were also receiving oral and/
or enteral nutrition (EN).
Parenteral TE Doses (Tables 3 and 4)
The most commonly used TE supplementation dose in 
PN was the 1-mL fixed dose of the multi-TE concentrate 
that combined all 5 trace elements (Table 1).
Zinc. The mean daily dose of zinc was 7.65 ± 0.74 mg. 
SBS patients received a higher zinc dose as compared to 
non-SBS patients, but the difference was not statistically 
significant (9.12 ± 1.15 vs 6.73 ± 0.91 mg, respectively; 
P = .12). In comparison to A.S.P.E.N.’s daily parenteral 
zinc supplementation guidelines, 26,872 (66.4%) doses 
were within and 13,621 (33.6%) doses were above the 
dosing ranges.
Selenium. The mean daily selenium dose was 69.14 ± 
2.56 mcg. Selenium doses were not significantly different 
between SBS patients and non-SBS patients (70.12 ± 
4.19 vs 68.54 ± 3.31 mcg, respectively; P = .76). In com-
parison to A.S.P.E.N.’s daily parenteral selenium supple-
mentation guidelines, 25,107 (62%) doses were within 
and 15,386 (38%) doses were above the dosing ranges.
Table 3.  Daily Parenteral Trace Element Doses in Home Parenteral Nutrition
Trace Element
Mean Daily Trace  
Element Doses  Range P Valuea
Zinc 7.65 ± 0.74 mg 3−15
 SBS 9.12 ± 1.15 mg 5−15 .12
 Non-SBS 6.73 ± 0.91 mg 3−15
Selenium 69.14 ± 2.56 mcg 30−120
 SBS 70.12 ± 4.19 mcg 40−120 .76
 Non-SBS 68.54 ± 3.31 mcg 30−100
Copper 0.99 ± 0.03 mg 0−2
Manganese 0.47 ± 0.10 mg 0−0.5
Chromium 9.33 ± 0.42 mcg 0−20
All mean values are reported as mean ± SEM. SBS, short bowel syndrome.
aP values are for the differences between SBS and non-SBS patients.
Table 4.  Number of Daily Parenteral Trace Element Doses Below, Within, and Above Dosing Ranges in Comparison 
to A.S.P.E.N.’s Guidelines6,a
Trace Element Below (%) Within (%) Above (%)
Zinc 0 26,872 (66.4) 13,621 (33.6)
Selenium 0 25,107 (62.0) 15,386 (38.0)
Copper 756 (1.8) 1101 (2.7) 38,636 (95.5)
Manganese 3018 (7.4) 0 37,475 (92.6)
Chromium 4560 (11.3) 35,287 (87.1) 646 (1.6)
A.S.P.E.N., American Society for Parenteral and Enteral Nutrition.
aDaily parenteral trace element supplementation in parenteral nutrition according to the guidelines by A.S.P.E.N. for adolescents (up 
to 18 years of age and >40 kg): zinc 2–5 mg, selenium 40–60 mcg, copper 0.2–0.5 mg, manganese 0.04–0.1 mg, and chromium 
5–15 mcg; adults (>18 years of age and >40 kg): zinc 2.5–5 mg, selenium 20–60 mcg, copper 0.3–0.5 mg, manganese 0.06–0.1 mg, 
and chromium 10–15 mcg.
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Copper. The mean daily copper dose was 0.99 ± 0.03 mg 
and was mostly unchanged in the presence or absence of 
cholestasis. In comparison to A.S.P.E.N.’s daily parenteral 
copper supplementation guidelines, 756 (1.8%) doses were 
below, 1101 (2.7%) within, and 38,636 (95.5%) above the 
dosing ranges. Only 1 of the 5 patients who developed 
cholestasis during the course of PN therapy had copper 
supplementation intermittently withheld in PN.
Manganese. The mean daily manganese dose was 0.47 ± 
0.10 mg and was mostly unchanged in the presence or 
absence of cholestasis. In comparison to A.S.P.E.N.’s 
daily parenteral manganese supplementation guidelines, 
3018 (7.4%) doses were below and 37,475 (92.6%) doses 
were above the dosing ranges. Two of the 5 patients who 
developed cholestasis during the course of PN therapy 
had manganese supplementation intermittently withheld 
in their PN.
Chromium. The mean daily chromium dose was 9.33 ± 
0.42 mcg. In comparison to A.S.P.E.N.’s daily parenteral 
chromium supplementation guidelines, 4560 (11.3%) 
doses were below, 35,287 (87.1%) within, and 646 (1.6%) 
above the dosing ranges. Eight patients had chromium 
supplementation withheld in their PN in response to 
elevated serum chromium concentrations.
Serum TE Concentrations (Tables 5–7)
Zinc. The mean serum zinc concentration was 0.95 ± 0.24 
mcg/mL and did not differ significantly between SBS and 
non-SBS patients (0.99 ± 0.07 and 0.92 ± 0.06 mcg/mL, 
respectively; P = .47). Of 146 serum zinc concentrations 
measured, 59 (40.4%) were obtained from SBS patients 
and 87 (59.6%) from non-SBS patients (P = .87), and the 
overall majority (90.5%) of values were within the refer-
ence range.
Selenium. The mean serum selenium concentration was 
101 ± 24.39 ng/mL and did not differ significantly 
between SBS and non-SBS patients (105.3 ± 7.94 and 
98.76 ± 6.96 ng/mL, respectively; P = .5). Of 115 serum 
selenium concentrations measured, 47 (40.9%) were 
from SBS patients and 68 (59.1%) from non-SBS patients 
(P = .67), with overall 44 (38.2%) values below, 69 (60%) 
within, and 2 (1.8%) above the reference range.
Copper. The mean serum copper concentration was 1.25 
± 0.20 mcg/mL. Of 40 serum copper concentrations mea-
sured, 31 (77.5%) were within and 9 (22.5%) above the 
reference range. No serum copper concentrations were 
measured during periods of cholestasis.
Manganese. The mean serum manganese concentration 
was 1.69 ± 0.40 ng/mL. Of 37 serum manganese concen-
trations measured, the majority (94.6%) were above the 
reference range. No serum manganese concentrations 
were measured during periods of cholestasis. Serum man-
ganese concentrations were higher when manganese was 
supplemented as compared to when it was not supple-
mented in PN (1.78 ± 0.15 vs 1.28 ± 0.28 ng/mL, respec-
tively), although the difference was not statistically 
significant (P = .1).
Chromium. The mean serum chromium concentration 
was 2.82 ± 1.91 ng/mL. Of 50 serum chromium concen-
trations measured, the majority (96%) were above the 
Table 5.  Serum Trace Element Concentrations
Trace Element (No.)
Mean Serum Trace  
Element Concentrations        Rangea P Valueb
Zinc (146) 0.95 ± 0.24 mcg/mL 0.6−1.5
 SBS (59) 0.99 ± 0.07 mcg/mL 0.85−1.13 .47
 Non-SBS (87) 0.92 ± 0.06 mcg/mL 0.79−1.05
Selenium (115) 101.0 ± 24.39 ng/mL 54.5−143.86
 SBS (47) 105.30 ± 7.94 ng/mL 90.05−121.60 .50
 Non-SBS (68) 98.76 ± 6.96 ng/mL 84.93−112.59
Copper (40)c 1.25 ± 0.20 mcg/mL 0.95−1.73
Manganese (37)c 1.69 ± 0.40 ng/mL 0.90−2.30
Chromium (50) 2.82 ± 1.91 ng/mL 0.51−6.85
All mean values are reported as mean ± SD, except for SBS and non-SBS values, which are mean ± SEM. SBS, short bowel 
syndrome.
aSerum reference ranges: zinc 0.55–1.50 mcg/mL, selenium 95–165 ng/mL, copper 0.7–1.4 mcg/mL (males) and 0.7–1.6 mcg/mL 
(females), manganese 0.40–0.85 ng/mL, and chromium <0.3 ng/mL.
bP values are for the differences between SBS and non-SBS patients.
cNo serum copper or manganese concentrations were obtained during periods of cholestasis.
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reference range. Serum chromium concentrations were 
significantly higher when chromium was supplemented as 
compared to when chromium supplementation was with-
held in PN (3.18 ± 0.49 vs 1.83 ± 0.52 ng/mL, respec-
tively; P < .0001).
Frequency of Monitoring Serum TE 
Concentrations (Table 8)
Serum TE concentrations were monitored at the discretion 
of prescribers and/or home care clinicians. They were mea-
sured at different time intervals during the course of PN 
Table 6.  Number of Serum Trace Element Concentrations Below, Within, and Above Reference Rangesa
Trace Element (No.) Below (%) Within (%) Above (%) P Valueb
Zinc (146) 8 (5.5) 132 (90.5) 6 (4.0)
 SBS (59) 3 (5.0) 53 (90.0) 3 (5.0) .87
 Non-SBS (87) 5 (5.8) 79 (90.8) 3 (3.4)
Selenium (115) 44 (38.2) 69 (60.0) 2 (1.8)
 SBS (47) 18 (38.3) 29 (61.7) 0 .67
 Non-SBS (68) 26 (38.2) 40 (58.8) 2 (3.0)
Copper (40)c 0 31 (77.5) 9 (22.5)
Manganese (37)c 0 2 (5.4) 35 (94.6)
Chromium (50) 0 2 (4.0) 48 (96.0)
All mean values are reported as mean ± SD, except for SBS and non-SBS values, which are mean ± SEM. SBS, short bowel 
syndrome.
aSerum reference ranges: zinc 0.55–1.50 mcg/mL, selenium 95–165 ng/mL, copper 0.7–1.4 mcg/mL (males) and 0.7–1.6 mcg/mL 
(females), manganese 0.40–0.85 ng/mL, and chromium <0.3 ng/mL.
bP values refer to comparisons of the differences between the percentages of measured serum zinc and selenium in SBS and non-SBS 
patients.
cNo serum copper or manganese concentrations were obtained during periods of cholestasis.
Table 7.  Serum Manganese and Chromium 
Concentrations in Patients Who Received Supplemented 
or Nonsupplemented Parenteral Nutrition Formulations
Trace Element
Mean Serum Trace 
Element Concentrations, 
ng/mLa P Valueb
Manganese
 Supplemented 1.78 ± 0.15 .1
 Nonsupplemented 1.28 ± 0.28
Chromium
 Supplemented 3.18 ± 0.49 <.0001
 Nonsupplemented 1.83 ± 0.52
All mean values are reported as mean ± SEM.
aSerum reference ranges: manganese 0.40–0.85 ng/mL and 
chromium <0.3 ng/mL.
bP values refer to comparisons of the differences in serum trace 
element concentrations in patients receiving supplemented or 
nonsupplemented parenteral nutrition formulations.
Table 8.  Measurement Frequency of Serum Trace 
Elements Concentrations
Trace Element
Mean Frequency of Serum 
Trace Element Measurement 
Per Year (Range) P Valuea
Zinc 1.21 ± 0.74 (0−2.38)
 SBS 1.45 ± 0.53 (0.56−2.13) .25
 Non-SBS 1.05 ± 0.82 (0−2.38)
Selenium 0.98 ± 0.74 (0−2.36)
 SBS 0.88 ± 0.75 (0−2.10) .35
 Non-SBS 0.88 ± 0.75 (0−2.10)
Copper 0.39 ± 0.59 (0−2.36)
Manganese 0.41 ± 0.59 (0−1.89)
Chromium 0.53 ± 0.69 (0−2.34)
All mean values are reported as mean ± SEM. SBS, short bowel 
syndrome.
aP values are for the differences between SBS and non-SBS 
patients.
therapy, and the timing and frequency of these measure-
ments varied widely among patients. The average frequen-
cies of annual monitoring of serum TE concentrations 
(average number of serum TE concentrations measured 
per year) were 1.21 ± 0.74 for zinc, 0.98 ± 0.74 for sele-
nium, 0.39 ± 0.59 for copper, 0.41 ± 0.59 for manganese, 
and 0.53 ± 0.69 for chromium. Although serum zinc con-
centrations were measured more frequently in SBS as 
compared to non-SBS patients (1.45 ± 0.53 and 1.05 ± 
0.82, respectively), the difference was not statistically signifi-
cant (P = .25). Serum selenium measurements were mea-
sured at a similar rate (0.88 ± 0.75) in SBS and non-SBS 
patients.
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Relationships Between TE Doses 
and Serum TE Concentrations
There was a significant relationship between overall 
zinc doses and serum zinc concentrations (P < .0001) 
and in patients with and without SBS (P = .004 and P = 
.002, respectively). Significant dose-concentration rela-
tionships were also found between supplemented TE 
doses and their corresponding serum concentrations for 
manganese (P = .012) and chromium (P < .0001). The 
relationship was not significant between overall selenium 
doses and serum selenium concentrations (P = .51) or 
between selenium doses and their serum concentrations 
in patients with and without SBS (P = .75 and P = .56, 
respectively). When the dose-concentration relationships 
were compared between SBS and non-SBS patients 
for zinc and selenium doses and their corresponding 
serum concentrations, the differences between the 2 
groups were not significant for either TE (P = .20 and 
P = .90, respectively). The relationship between copper 
doses and serum copper concentrations was not signifi-
cant (P = .77).
Discussion
The AMA parenteral TE supplementation guidelines have 
been historically used as the basis for adult TE supple-
mentation in PN.1,2 Following reports of TE imbalances 
with TE supplementation based on the AMA guidelines, 
the A.S.P.E.N. safe practice guidelines provided revised 
TE dosing requirements in PN.6 However, the fixed dose 
of parenteral multi-TE products that were formulated 
based on the old AMA guidelines has continued to be 
used. Furthermore, the outcomes of A.S.P.E.N. paren-
teral TE dosing recommendations on serum TE concen-
trations remain to be tested.
Zinc
Zinc plays a role in a variety of enzymatic, metabolic, and 
immunologic functions.13 Study results show that an 
average zinc dose of 7.6 mg/d in PN maintained normal 
serum zinc concentrations in the majority (90%) of cases. 
The zinc dose exceeded what is recommended in the lit-
erature and by the A.S.P.E.N. guidelines for 2.5–5 mg/d 
in adults without increased intestinal zinc 
losses.6,14,15However, the zinc dose in our study was simi-
lar to the suggested dose of 8 mg/d for home PN patients 
to achieve normal serum zinc concentrations.16 SBS 
patients required a higher zinc dose of about 9 mg/d as 
compared to 6.7 mg/d for non-SBS patients. These doses 
maintained normal serum zinc concentrations in about 
90% of cases. Zinc requirements are increased by about 
12 mg/L of small intestinal fluid volume, and SBS 
patients may lose up to 3.6 mg zinc per kg of intestinal 
fluid.14 Thus, similar to our study results, a parenteral 
zinc dose of 10 mg/d has been suggested for patients with 
high intestinal fluid losses.15 Because intestinal fluid 
losses are not typically collected or quantified in home 
care patients, it was difficult to provide an estimate of 
intestinal zinc losses. There was a strong relationship 
between zinc doses and serum zinc concentrations. This 
relationship has also been reported in studies with oral 
zinc supplementation, whereby serum zinc concentra-
tions showed a consistent and positive response when 
zinc intake exceeded 2–3 mg/d but reached a plateau 
when zinc intake exceeded 25–30 mg/d.13 In our study, 
zinc doses ranged from 3–15 mg/d, which may explain the 
observed strong relationship between zinc doses and 
serum zinc concentrations within this dosing range. 
Overall, the frequency of measuring serum zinc concen-
trations was low at 1.21 measurements per year. Although 
serum zinc concentrations were measured about 1.4 
times more frequently in SBS than in non-SBS patients, 
the difference was not significant. The relatively more 
frequent measurements of serum zinc concentrations in 
SBS patients may be related to clinicians’ awareness of 
the higher risk of zinc deficiency in SBS patients and the 
need for more frequent monitoring.
Selenium
Selenium is a cofactor of the glutathione peroxidase 
enzyme, the major antioxidant in the body.17 Although the 
average selenium dose of about 70 mcg/d exceeded the 
A.S.P.E.N. maintenance dosing guidelines, about 38% of 
serum selenium concentrations were below normal in SBS 
and non-SBS patients alike. Although a minimum sele-
nium dose of 50 mcg/d and a usual dose of 60 mcg/d have 
been recommended in PN,15,17 our data show that even a 
higher parenteral selenium dose of about 70 mcg/d 
achieved normal serum selenium concentrations in only 
about 60% of cases. Higher maintenance selenium doses 
of 60–100 mcg/d have been actually suggested for adult 
home PN patients, and patients with selenium depletion 
may require even higher doses.18 Selenium deficiency has 
been reported in SBS patients due to increased selenium 
losses in intestinal fluids.19 In a study of non-SBS home 
PN patients, daily parenteral selenium doses of 63 mcg 
resulted in a wide range of serum selenium concentrations 
of 17.5–131 ng/mL, with 16% of values below normal 
levels.16 In another study of home PN patients that 
included 5 patients with SBS, parenteral selenium 80 
mcg/d followed by 160 mcg/d increased but did not con-
sistently normalize serum selenium concentrations.20 
Higher selenium doses up to 250–400 mcg/d have been 
suggested to correct severe selenium deficiencies.15,21 
Therefore, higher selenium doses than what is recom-
mended by the A.S.P.E.N. guidelines for parenteral sele-
nium supplementation are needed to maintain normal 
serum selenium concentrations for the majority of home 
PN patients, especially when high selenium losses occur. 
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There was no significant relationship between selenium 
doses and serum selenium concentrations in SBS and non-
SBS patients. Although in a prior study, plasma selenium 
concentrations increased with increasing selenium doses, 
there was no correlation between selenium doses and 
plasma selenium concentrations.20 After initial gradual 
increase of serum selenium concentrations, selenium 
doses of 200 mcg/d for 3 months or 100 mcg/d for 8 
months resulted in no significant change in serum sele-
nium concentrations.21 This might be explained by the 
observation that a correlation exists between selenium 
intake and serum selenium concentrations up to 70 ng/
mL, above which a plateau is formed.19 The plateau effect 
might explain our study results that found no relationship 
between selenium doses and serum selenium concentra-
tions. Overall, the frequency of measuring serum sele-
nium concentrations was low at 0.98 measurements per 
year and was similar in SBS and non-SBS patients. 
Plasma or serum selenium concentrations are most used 
to assess selenium status, but their usefulness for moni-
toring the changes in selenium intake has been ques-
tioned as they reflect acute selenium distribution between 
tissues rather than selenium stores.17,18 The erythrocyte 
glutathione peroxidase activity may better reflect long-
term selenium status, although it is not commonly used in 
clinical practice. The role of platelet and plasma glutathi-
one peroxidase activity as indicators of selenium status is 
debatable.17,20,21
Copper
Copper plays a role in hematopoiesis, connective tissue 
synthesis, and oxidative enzymes.17 Study results show 
that the average daily copper dose far exceeded A.S.P.E.N.’s 
guidelines, and most (95.5%) of the doses were above the 
recommended dosing range. Serum copper concentra-
tions were maintained within the normal range in 77.5% 
of cases, with the remaining serum concentrations above 
normal levels. In a similar study of home PN patients, 
copper 1 mg/d resulted initially in serum copper concen-
trations of 1.35 + 0.25 mcg/mL, then increased to 1.79 + 
0.33 mcg/mL after 6 months of copper supplementation, 
with serum copper concentrations frequently above the 
reference range.22 When a lower copper dose of 0.13 
mg/d was in home PN, serum copper concentrations var-
ied widely from 0.5–3.17 mcg/L, with 62.5% of values 
within, 34.3% below, and 3.2% above normal.16 In com-
parison to the latter study, our study results show that a 
7.6-fold higher copper dose (0.99 mg/d) resulted in 22.5% 
of serum copper concentrations above normal. As such, 
copper dosing based on A.S.P.E.N.’s guidelines for copper 
supplementation in PN represents an intermediate dosing 
between the lower copper doses used16 and the higher 
AMA dosing guidelines.1 In addition to standard copper 
supplementation in PN, copper contaminants in PN solu-
tions may provide additional copper loading as much as 
2-fold higher than recommended for copper supplementa-
tion.23 Because copper is primarily eliminated via the bile, 
its excretion is decreased in patients with reduced bile flow 
such as cholestasis. Although copper may accumulate in 
patients with cholestasis, caution is needed when copper 
supplementation is restricted. Copper deficiency has been 
reported within 6 weeks to 15 months after copper was 
omitted from the PN of patients with cholestasis, resulting 
in pancytopenia and fatalities.24-27 Although copper toxicity 
has not been reported in PN patients, hepatic copper accu-
mulation may still occur.28 Autopsies of SBS patients who 
received copper doses of 1.4 mg/d in their home PN 
showed copper accumulation in the liver and kidneys, 
especially in patients who died of liver failure.3 This raises 
the concern for potential subclinical copper toxicity that 
may occur in home PN patients, especially when higher 
doses are used. Because there is no simple way to clinically 
measure bile flow, it is difficult to estimate the amount of 
copper elimination in the bile. It is also difficult to predict 
the duration of copper supplementation that predisposes to 
copper accumulation, and hepatic copper loading does not 
correlate with the duration of copper supplementation in 
home PN.28 In our study, serum copper concentrations 
were not measured during cholestasis, and copper doses 
were likely adjusted empirically based on clinicians’ experi-
ence whenever serum bilirubin concentrations became 
elevated. The average frequency of serum copper concen-
trations measurements was low at 0.39 per year. Although 
serum copper concentrations do not accurately reflect cop-
per accumulation, it is prudent to regularly measure serum 
copper concentrations in long-term PN patients. Copper 
supplementation should be conservative in patients with 
cholestasis with regular monitoring of copper status to 
avoid deficiency.15,28 The relationship between copper 
doses and serum copper concentrations was not signifi-
cant. Because serum copper concentrations were not mea-
sured during cholestasis, we could not compare this 
relationship between patients with and without cholestasis.
Manganese
Manganese is a component of metalloenzymes and is 
associated with oxidative phosphorylation and mucopoly-
saccharide metabolism.17,29 The majority (92.6%) of man-
ganese doses far exceeded the upper limit of A.S.P.E.N. 
supplementation guidelines. The average serum manga-
nese concentration was about 2-fold higher than the upper 
end of the serum manganese reference range. An average 
manganese dose of 0.47 mg/d resulted in about 95% of 
serum manganese concentrations above normal. In 1 
study, a lower manganese dose of 0.28 mg/d in PN resulted 
in about 97% of serum manganese concentrations above 
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the normal range.16 Patients who received manganese in 
their PN had 1.4-fold higher serum manganese concen-
trations as compared to those who did not receive manga-
nese supplementation. Serum manganese concentrations 
remained elevated even after manganese was omitted 
from PN. One patient without cholestasis had elevated 
serum manganese concentrations after 349 days of man-
ganese removal from PN. This might be explained by the 
manganese contaminants of parenteral products that are 
used in the making of PN. Manganese contaminants in 
PN can be as high as 0.31 mg/L, with dextrose and elec-
trolyte solutions contributing as much as 0.038 
mg/L.6,10,30-32 Home PN patients have had elevated serum 
manganese concentrations after more than 10 years of 
eliminating manganese from their PN.33 Because manga-
nese is mostly excreted in the bile, manganese accumula-
tion occurs in patients with cholestasis. Manganese 
deposits in the basal ganglia, causing neurological toxic-
ity, have been shown on magnetic resonance imaging 
(MRI) of home PN patients with elevated serum manga-
nese concentrations. Manganese loading may also cause 
liver toxicity and cholestasis.34,35 Manganese doses were 
not consistently reduced and no serum manganese con-
centrations were measured during cholestasis. We found 
a significant relationship between manganese doses and 
serum manganese concentrations. This is similar to the 
results of another study that showed a relationship 
between manganese supplementation in PN and whole-
blood manganese concentrations in patients who received 
home PN for up to 226 months.36 However, this is in 
contrast to another study that showed no association 
between manganese doses and serum and whole-blood 
manganese concentrations.33 Although serum manganese 
concentrations are frequently used to assess manganese 
status in PN patients, whole-blood manganese concentra-
tions are believed to be more representative of manganese 
status.37 The frequency of measuring serum manganese 
concentrations was only at 0.41 measurements per year. 
This was a low rate of monitoring considering the risk of 
manganese accumulation in long-term PN patients.9
Chromium
Chromium is a cofactor for insulin function that enhances 
insulin effects to improve glucose metabolism through 
the glucose tolerance factor.38 In comparison to 
A.S.P.E.N.’s guidelines, the majority (87.1%) of chro-
mium doses were within the dosing range. However, the 
vast majority (96%) of serum chromium concentrations 
far exceeded the reference range. Patients who received 
chromium in their PN had significantly 1.73-fold higher 
serum chromium concentrations as compared to those 
who received no chromium supplementation. Serum 
chromium concentrations remained elevated even when 
chromium was not supplemented. In 2 patients, serum 
chromium concentrations remained elevated after receiv-
ing chromium-free PN for 1.3 and 2 years, respectively. 
These findings may reflect excess chromium intake from 
chromium contaminants. None of the patients had 
decreased renal function during the study, which rules 
out any chromium accumulation secondary to acute or 
chronic kidney injury. Chromium contamination in PN is 
well documented and varies between manufacturers and 
product lots.12,39-43 Chromium contaminants in parenteral 
products may contribute up to 100% more of chromium 
intake,43 causing up to a 40-fold increase in serum chro-
mium concentrations and substantially higher tissue 
chromium accumulation.40 In our study, serum chro-
mium concentrations reached about 23-fold (6.85 ng/
mL) the upper reference range (0.3 ng/mL). This is simi-
lar to reported data of serum chromium concentrations 
exceeding 21 times the upper level of normal.40 Although 
chromium toxicity in PN patients has not been reported, 
there are concerns of possible association between high 
serum chromium concentrations and decreased kidney 
function in children.43 To the contrary, glucose intoler-
ance and neuropathy were linked to chromium deficiency 
in early studies of home PN patients.44-46 In long-term PN 
patients, supplemental chromium may not be necessary, 
and chromium supplementation based on A.S.P.E.N.’s 
guidelines may be excessive, considering the significance 
of chromium contamination of PN solutions. Serum 
chromium concentrations were measured at a low fre-
quency of 0.53 measurements per year. Considering the 
extent of chromium contamination, serum chromium 
concentrations should be measured more frequently at 
shorter intervals in home PN patients.39 Although serum 
chromium concentrations are the most widely used to 
monitor chromium status in PN patients, no correlation 
was found between serum chromium and tissue chro-
mium stores.47 However, we found a strong relationship 
between chromium doses and serum chromium concen-
trations. The interpretation of this relationship is difficult 
considering the unknown but possibly significant amounts 
of chromium contaminants in PN solutions that may have 
affected serum chromium concentrations.
Summary
The FDA-labeled adult parenteral multi-TE formulation 
that is available in the United States is based on the out-
dated AMA recommendations and indirectly encourages 
the use of the fixed-dose multi-TE product that does not 
accurately meet the TE requirements for home PN patients. 
Although the parenteral multi-TE product provides the 
convenience of providing all TEs in one dose, a fixed dose 
may not fit individual TE requirements for long-term PN 
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patients. The A.S.P.E.N. guidelines for daily TE supple-
mentation in PN formulations represent approximations of 
standard TE intakes in the healthy population and assume 
normal losses and age-related organ function. Interindividual 
variations for TE requirements may exist, and intakes can 
best be achieved by using individualized TE products.6 In 
comparison to the A.S.P.E.N. guidelines for maintenance 
TE supplementation in PN, our study results show that 
long-term home PN patients >40 kg may require higher 
zinc and selenium doses to maintain their serum concen-
trations within the normal range, especially when high 
intestinal losses occur. Lower copper and manganese doses 
are needed especially in the setting of cholestasis. Lower 
manganese and chromium doses are required to avoid 
accumulation, especially when PN contaminants are con-
sidered. These can only be achieved by individualizing TE 
supplementation based on regular monitoring of TE status 
and according to underlying clinical conditions.
The frequency of monitoring TE status in long-term 
home PN has not been well documented and has been 
mostly dependent on clinicians’ practice experiences. Our 
study results show infrequent and random monitoring of 
serum TE concentrations in long-term home PN patients. 
Therefore, guidelines and standards for regular monitor-
ing of TE status should be implemented to improve the 
safety and efficacy of PN therapy. Although it may not be 
possible to completely eliminate TE contaminants from 
parenteral products, the FDA should consider requiring 
manufacturers to specify the maximum safe or allowable 
TE contamination limits in parenteral products, similar to 
the case of aluminum.48
The relationship between parenteral TE doses and 
serum TE concentrations in PN patients has not been 
explored sufficiently because of complex TE kinetics 
related to tissue distribution and elimination and the vari-
ability of underlying conditions that affect TE balance. In 
our study, the dose-concentration relationships between 
TE doses and serum TE concentrations were significant for 
zinc, manganese, and chromium but were less predictable 
for selenium and copper. The clinical significance of these 
relationships requires further evaluation.
Study Limitations
The study findings emphasize the importance of accu-
rately dosing and monitoring TE status in home PN 
patients but present with some limitations, especially 
those inherent to a retrospective observational study 
design. Data collected were based on the assumption that 
any prescribed home PN was administered to the patient, 
although no actual home PN administration records were 
available to confirm the actual PN infusions. Furthermore, 
we assumed that total TE doses were delivered to patients, 
although PN storage and temperature can significantly 
decrease zinc, copper, and manganese availability in 
home PN solutions that are typically compounded and 
delivered in batches of 7–10 days for home supply.49 
Because serum direct bilirubin concentrations were not 
measured at regular intervals and we did not consider the 
clinical signs and symptoms in the diagnosis of cholesta-
sis, it was therefore difficult to ascertain the exact dura-
tion of cholestasis. Also, other TE sources such as PN 
contaminants, diet, EN, or oral supplements, were not 
considered, which may have influenced the results. Of 
note, dose-concentration relationships do not constitute 
pharmacokinetic models to predict serum TE concentra-
tions in relation to TE doses, and serum TE concentra-
tions do not determine the chemical form of a particular 
element, biologic activity, or availability in the body as a 
whole and may not represent actual body stores.50-52 
Serum TE concentrations do not necessarily reflect total 
body TE stores, and levels are affected by the response to 
stress or injury. Although tissue TE redistribution occurs 
during the phase of the inflammatory response to stress, 
this is typically significant in acutely ill or hospitalized 
patients53 and is of a lesser significance in stable home 
PN patients. Because inflammatory markers (eg, serum 
C-reactive protein or CRP levels) are not routinely mea-
sured in the home setting, we could not assess the level 
of the inflammatory process and its possible effects on 
serum TE concentrations. When zinc and selenium 
supplementation and their serum concentrations were 
compared between SBS and non-SBS patients, the non-
SBS population included patients with malabsorption 
disorders who may have also had intestinal TE losses. 
However, SBS patients have exceedingly high intestinal 
zinc and selenium losses due to short intestinal surface 
absorption area, rapid gastrointestinal transit time, and 
chronic diarrhea. Last, we could not locate any docu-
mentation of clinical signs and symptoms of TE deficien-
cies or toxicities, and thus we cannot speculate on the 
clinical consequences of low or high serum TE concen-
trations.
Another limitation is related to possible manganese 
and chromium needle contamination during blood sam-
pling. This is of particular interest given the observed 
high serum chromium and manganese concentrations 
when neither TE was deliberately supplemented in PN. 
Chromium and manganese are known to leach from 
metal needles.54,55 However, contamination control was 
followed during specimen sampling and collection by 
using metal-free syringes and special metal-free TE blood 
collection tubes. The magnitude of steel needle contami-
nation risk is likely minimal when the contact time 
between the needle and blood sample is kept at a mini-
mum, which is the typical technique followed during 
blood sampling and collection.56
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Conclusions
Parenteral TE dosing should be individualized for home 
PN patients rather than using a fixed-dose multi-TE prod-
uct. TE dose adjustments should be guided by regular 
monitoring of TE status. Higher than maintenance zinc 
and selenium doses may be required to maintain normal 
serum zinc and selenium concentrations in long-term 
home PN patients, especially under conditions of increased 
intestinal losses. Lower copper doses may be necessary to 
avoid long term copper accumulation. Excessive manga-
nese and chromium loading occurs in long-term PN 
patients, and restriction of manganese and chromium 
supplementation may be required to avoid their accumula-
tion. The dose-concentration relationships between TE 
doses and serum concentrations vary with each TE and 
underlying clinical conditions.
Acknowledgment
We thank Haider Al-wishah, PharmD, for his assistance 
with data collection and entry, and Jamie C. Tharp, 
PharmD, and Susan K. Bickley, PharmD, for their guid-
ance.
References
 1. American Medical Association Department of Foods and Nutrition. 
Guidelines for essential trace element preparations for parenteral 
use: a statement by an expert panel. JAMA. 1979;241:2051–2054.
 2. Shils ME, White PL, eds. Working conference on parenteral trace 
elements: sponsored by N.Y. Acad. Med and AMA. Bull NY Acad 
Med. 1984;60:115–212.
 3. Howard L, Ashley C, Lyon D, Shenkin A. Autopsy tissue trace ele-
ments in 8 long-term parenteral nutrition patients who received 
the current U.S. Food and Drug Administration formulation. JPEN 
J Parenter Enteral Nutr. 2007;31:109–108.
 4. Leung FY. Trace elements in parenteral micronutrition. Clin 
Biochem. 1995;28:561–566.
 5. The American Society for Parenteral and Enteral Nutrition 
(A.S.P.E.N.). Safe practices for parenteral nutrition formulations. 
National Advisory Group on Standards and Practice Guidelines for 
Parenteral Nutrition. JPEN J Parenter Enteral Nutr. 1998;22:49–66.
 6. Mirtallo J, Canada T, Johnson D, et al. Task Force for the Revision 
of Safe Practices for Parenteral Nutrition: safe practices for paren-
teral nutrition. JPEN J Parenter Enteral Nutr. 2004;28:S39–S70.
 7. Taylor S, Manara AR. Manganese toxicity in a patient with choles-
tasis receiving total parenteral nutrition. Anaesthesia. 1994;49:1013.
 8. Wardle CA, Forbes A, Roberts NB, Jawhari AV, Shenkin A. 
Hypermanganesemia in long-term intravenous nutrition and chronic 
liver disease. JPEN J Parenter Enteral Nutr. 1999;23:350–355.
 9. Reimund JM, Dietemann JL, Warter JM, Baumann R, Duclos B. 
Factors associated to hypermanganesemia in patients receiving 
home parenteral nutrition. Clin Nutr. 2000;19:343–348.
 10. Pluhator-Murton MM, Fedorak RN, Audette RJ, Marriage BJ, 
Yatscoff RW, Gramlich LM. Trace element contamination of total 
parenteral nutrition: 1. Contribution of component solutions. 
JPEN J Parenter Enteral Nutr. 1999;23:222–227.
 11. Berner YN, Shuler TR, Nielsen FH, Flombaum C, Farkouh SA, 
Shike M. Selected ultratrace elements in total parenteral nutrition 
solutions. Am J Clin Nutr. 1989;50:1079–1083.
 12. Ito Y, Alcock NW, Shils ME. Chromium content of total parenteral 
nutrition solutions. JPEN J Parenter Enteral Nutr. 1990;14:610–614.
 13. Gibson RS, Hess SY, Hotz C, Brown KH. Indicators of zinc status 
at the population level: a review of the evidence. Br J Nutr. 
2008;99(Suppl 3):S14–23.
 14. Wolman SL, Anderson GH, Marliss EB, Jeejeebhoy KN. Zinc in 
total parenteral nutrition: requirements and metabolic effects. 
Gastroenterology. 1979;76:458–467.
 15. Frankel DA. Supplementation of trace elements in parenteral nutri-
tion: rationale and recommendations. Nutr Res. 1993;13:583–596.
 16. Forbes GM, Forbes A. Micronutrient status in patients receiving 
home parenteral nutrition. Nutrition. 1997;13:941–944.
 17. Sriram K, Lonchyna VA. Micronutrient supplementation in adult 
nutrition therapy: practical considerations. JPEN J Parenter Enteral 
Nutr. 2009;33:548–562.
 18. Shenkin A. Selenium in intravenous nutrition. Gastroenterology. 
2009;137(5)(suppl):S61–S69.
 19. Rannem T, Hylander E, Ladefoged K, Staun M, Tjellesen L, 
Jarnum S. The metabolism of (75Se)selenite in patients with short 
bowel syndrome. JPEN J Parenter Enteral Nutr. 1996;20:412–416.
 20. Lane HW, Lotspeich CA, Moore CE, Ballard J, Dudrick SJ, Warren 
DC. The effect of selenium supplementation on selenium status of 
patients receiving chronic total parenteral nutrition. JPEN J 
Parenter Enteral Nutr. 1987;11:177–182.
 21. Rannem T, Ladefoged K, Hylander E, Hegnhoj J, Jarnum S. Selenium 
depletion in patients on home parenteral nutrition: the effect of sele-
nium supplementation. Biol Trace Element Res. 1993;39:81–90.
 22. Davis AT, Franz FP, Courtnay DA, Ullrey DE, Scholten DJ, Dean 
RE. Plasma vitamin and mineral status in home parenteral nutri-
tion patients. JPEN J Parenter Enteral Nutr. 1987;11:480–485.
 23. Hauer EC, Kaminiski MV. Trace metal profile of parenteral nutri-
tion solutions. Am J Clin Nutr. 1978;31:264–268.
 24. Wasa M, Satani M, Tanano H, et al. Copper deficiency with pan-
cytopenia during total parenteral nutrition. JPEN J Parenter Enteral 
Nutr. 1994;18:190–192.
 25. Spiegel JE, Willenbucher RF. Rapid development of severe copper 
deficiency in a patient with Crohn’s disease receiving parenteral 
nutrition. JPEN J Parenter Enteral Nutr. 1999;23:169–172.
 26. Fuhrman MP, Herrmann V, Masidonski P, et al. Pancytopenia after 
removal of copper from total parenteral nutrition. JPEN J Parenter 
Enteral Nutr. 2000;24:361–366.
 27. Hurwitz M, Garcia MG, Poole RL, Kerner JA. Copper deficiency 
during parenteral nutrition: a report of four pediatric cases. Nutr 
Clin Pract. 2004;19:305–308.
 28. Blaszyk H, Wild PJ, Oliveira A, Kelly DG, Burgart LJ. Hepatic cop-
per in patients receiving long-term total parenteral nutrition. J Clin 
Gastroenterol. 2005;39:318–320.
 29. Aschner JL, Aschner M. Nutritional aspects of manganese homeo-
stasis. Mol Aspects Med. 2005;26:353–362.
 30. Buchman AL, Neely M, Grossie VB Jr, et al. Organ heavy-metal 
accumulation during parenteral nutrition is associated with patho-
logic abnormalities in rats. Nutrition. 2001;17:600–606.
 31. Takagi Y, Okada A, Sando K, et al. Evaluation of indexes of in vivo 
manganese status and the optimal intravenous dose for adult 
patients undergoing home parenteral nutrition. Am J Clin Nutr. 
2002;75:112–118.
 32. Hardy G, Reilly C. Technical aspects of trace element supplemen-
tation. Curr Opin Clin Nutr Metab Care. 1999;2:277–285.
 33. Siepler JK, Nishikawa RA, Diamantidis T, Okamoto R. 
Asymptomatic hypermanganesemia in long-term home parenteral 
nutrition patients. Nutr Clin Pract. 2003;18:370–373.
 34. Fell JM, Reynolds AP, Meadows N, et al. Manganese toxicity in 
children receiving long term parenteral nutrition. Lancet. 
1996;347:1218–1221.
 35. Reynolds AP, Kiely E, Meadows N. Manganese in the long term 
paediatric parenteral nutrition. Arch Dis Child. 1994;71:527–528.
 36. Takagi Y, Okada A, Sando K, Wasa M, Yoshida H, Hirabuki N. 
On-off study of manganese administration to adult patients 
 at Lebanese American University on October 10, 2016pen.sagepub.comDownloaded from 
Dosing and Monitoring of Trace Elements in Long-Term Home PN / Btaiche et al  747
undergoing home parenteral nutrition: new indices of in vivo man-
ganese level. JPEN J Parenter Enteral Nutr. 2001;25:87–92.
 37. Hardy G. Manganese in parenteral nutrition: who, when, and why 
should we supplement? Gastroenterology. 2009;137(5)(suppl):S29–
S35.
 38. Mertz W. Chromium in human nutrition: a review. J Nutr. 
1993;123:626–633.
 39. Anderson RA. Chromium and parenteral nutrition. Nutrition. 
1995;11(1)(suppl):83–86.
 40. Leung FY, Galbraith LV. Elevated serum chromium in patients on 
total parenteral nutrition and the ionic species of contaminant 
chromium. Biol Trace Elem Res. 1995;50:221–228.
 41. Mouser JF, Hak EB, Helms RA, Christensen ML, Storm MC. Chromium 
and zinc concentrations in pediatric patients receiving long-term par-
enteral nutrition. Am J Health Syst Pharm. 1999;56:1950–1956.
 42. Hak EB, Storm MC, Helms RA. Chromium and zinc contamina-
tion of parenteral nutrient solution components commonly used in 
infants and children. Am J Health Syst Pharm. 1998;55:150–154.
 43. Moukarzel AA, Song MK, Buchman AL, et al. Excessive chromium 
intake in children receiving total parenteral nutrition. Lancet. 
1992;339:385–388.
 44. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-
Robertson A. Chromium deficiency, glucose intolerance, and neu-
ropathy reversed by chromium supplementation, in a patient 
receiving long-term total parenteral nutrition. Am J Clin Nutr. 
1977;30:531–538.
 45. Freund H, Atamian S, Fischer JE. Chromium deficiency during 
total parenteral nutrition. JAMA. 1979;241:496–498.
 46. Brown RO, Forloines-Lynn S, Cross RE, Heizer WD. Chromium 
deficiency after long-term total parenteral nutrition. Dig Dis Sci. 
1986;31:661–664.
 47. Lim TH, Sargent T III, Kusubov N. Kinetics of trace element chromium 
(III) in the human body. Am J Physiol. 1983;244:R445–R454.
 48. Food and Drug Administration. Aluminum in large and small vol-
ume parenterals used in total parenteral nutrition. Fed Regist. 
2000;6:4103–4111.
 49. Pluhator-Murton MM, Fedorak RN, Audette RJ, Marriage BJ, 
Yatscoff RW, Gramlich LM. Trace element contamination of total 
parenteral nutrition: 2. Effect of storage duration and temperature. 
JPEN J Parenter Enteral Nutr. 1999;23:228–232.
 50. Harraki B, Guiraud P, Rochat MH, Alary J, Favier A. Interactions 
related to trace elements in parenteral nutrition. Pharm Acta Helv. 
1995;70:269–278.
 51. Hambidge M. Biomarkers of trace mineral intake and status. J 
Nutr. 2003;133(suppl 3):948S–955S.
 52. Hotz C, Lowe NM, Araya M, Brown KH. Assessment of the trace 
element status of individuals and populations: the example of zinc 
and copper. J Nutr. 2003;133(5)(suppl 1):1563S–1568S.
 53. Berger MM, Shenkin A. Trace element requirements in critically 
ill burned patients. J Trace Elem Med Biol. 2007;21(suppl 1):44–
48.
 54. Yang JM, Lewandrowski KB. Trace elements, vitamins, and 
nutrition. In: McClatchey KD, ed. Clinical Laboratory Medicine. 
2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2002: 
439–462.
 55. Cornelis R, Heinzow B, Herber RF, et al. Sample collection guide-
lines for trace elements in blood and urine. IUPAC Commission of 
Toxicology. J Trace Elem Med Biol. 1996;10:103–127.
 56. Varga I. Assessment of the contamination problems resulting from 
the use of stainless steel needles in liver biopsies by total reflection 
X-ray fluorescence and inductively coupled plasma mass spectrom-
etry. Spectrochimica Acta. 2006;61:1201–1204.
 at Lebanese American University on October 10, 2016pen.sagepub.comDownloaded from 
